Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious Diseases in Animals
4.2.2 Technological Advancements in Development of New Drugs
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Antibiotics
5.1.2 Antiviral
5.1.3 Antifungal
5.1.4 Amebicides
5.1.5 Others
5.2 By Animal Type
5.2.1 Dogs and Cats
5.2.2 Horses
5.2.3 Swine
5.2.4 Poultry
5.2.5 Other Animals
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Elanco
6.1.2 Merck & Co. Inc
6.1.3 Boehringer Ingelheim Vetmedica, Inc.
6.1.4 Zoetis Inc.
6.1.5 Dechra Pharmaceuticals PLC
6.1.6 Ceva Sant? Animale
6.1.7 Virbac S.A
6.1.8 Bayer AG
6.1.9 Vetoquinol S.A
6.1.10 IDEXX Laboratories, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS